Related Experiment Video

Updated: Jun 29, 2025

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
07:08

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein

Published on: January 16, 2020

5.7K

Progress in Targeting KRAS Directly

Dwight V Nissley1, Andrew G Stephen2, Ming Yi2

  • 1NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA. dwight.nissley@nih.gov.

Methods in Molecular Biology (Clifton, N.J.)
|April 3, 2024
PubMed

Insights

RAS research is advancing translational cancer science by targeting RAS mutations, especially in KRAS. Understanding these proteins and their signaling pathways enables new therapeutic strategies for cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • RAS mutations are key drivers in various cancers.
  • Understanding RAS protein properties (biochemical, structural, biophysical) is crucial.
  • KRAS is a primary focus in RAS research.

Purpose of the Study:

  • To highlight progress in RAS research for translational and clinical science.
  • To discuss the role of RAS mutations in cancer.
  • To explore chemical approaches for targeting RAS proteins, particularly KRAS.

Main Methods:

  • Appreciation of the role of RAS mutations in cancer.
  • Analysis of the biochemical, structural, and biophysical properties of RAS proteins.
  • Investigation of RAS signaling pathways in normal and cancer cells.

Main Results:

  • Enabled creative chemical approaches to directly target KRAS.
  • Provided a foundation for developing RAS inhibitors.
  • Revealed new strategies for targeting RAS via signaling complexes and downstream pathways.

Conclusions:

  • Continued research into RAS mutations and signaling pathways is vital for cancer therapy.
  • Targeting KRAS directly and disrupting its signaling network are promising therapeutic avenues.
  • Translational and clinical advancements in RAS research offer new hope for cancer patients.
Keywords:
GTP hydrolysisMutation frequency in cancerOncogenic allelesRASTargeting RAS

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.9K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.2K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K